156 related articles for article (PubMed ID: 37812190)
1. An immune signature to predict the prognosis of
Cao W; Sun P; Luo S; Zeng Z; Xiao C; Yu W; Lei S
Aging (Albany NY); 2023 Oct; 15(19):10453-10472. PubMed ID: 37812190
[TBL] [Abstract][Full Text] [Related]
2. A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.
Zeng Z; Hu C; Ruan W; Zhang J; Lei S; Yang Y; Peng P; Pan F; Chen T
Front Immunol; 2022; 13():1001381. PubMed ID: 36159801
[TBL] [Abstract][Full Text] [Related]
3. [Application of ATRX in diagnosis and prognostic evaluation of glioma].
Li Z; Piao YS; Zhang LY; Wang LM; Wang DD; Fu YJ; Cai YN; Lu DH
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):690-694. PubMed ID: 29050070
[No Abstract] [Full Text] [Related]
4. ATRX regulates glial identity and the tumor microenvironment in IDH-mutant glioma.
Babikir H; Wang L; Shamardani K; Catalan F; Sudhir S; Aghi MK; Raleigh DR; Phillips JJ; Diaz AA
Genome Biol; 2021 Nov; 22(1):311. PubMed ID: 34763709
[TBL] [Abstract][Full Text] [Related]
5. Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.
Cao W; Lan J; Hu C; Kong J; Xiang L; Zhang Z; Sun Y; Zeng Z; Lei S
Aging (Albany NY); 2024 Mar; 16(6):5618-5633. PubMed ID: 38499392
[TBL] [Abstract][Full Text] [Related]
6. Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature.
Li Y; Liu X; Qian Z; Sun Z; Xu K; Wang K; Fan X; Zhang Z; Li S; Wang Y; Jiang T
Eur Radiol; 2018 Jul; 28(7):2960-2968. PubMed ID: 29404769
[TBL] [Abstract][Full Text] [Related]
7. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
8. Loss of ATRX suppresses ATM dependent DNA damage repair by modulating H3K9me3 to enhance temozolomide sensitivity in glioma.
Han B; Cai J; Gao W; Meng X; Gao F; Wu P; Duan C; Wang R; Dinislam M; Lin L; Kang C; Jiang C
Cancer Lett; 2018 Apr; 419():280-290. PubMed ID: 29378238
[TBL] [Abstract][Full Text] [Related]
9. Interferon gamma-related gene signature based on anti-tumor immunity predicts glioma patient prognosis.
Zhang Z; Shen X; Tan Z; Mei Y; Lu T; Ji Y; Cheng S; Xu Y; Wang Z; Liu X; He W; Chen Z; Chen S; Lv Q
Front Genet; 2022; 13():1053263. PubMed ID: 36712869
[No Abstract] [Full Text] [Related]
10. A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma.
Luo C; Wang S; Shan W; Liao W; Zhang S; Wang Y; Xin Q; Yang T; Hu S; Xie W; Xu N; Zhang Y
Front Immunol; 2022; 13():909189. PubMed ID: 35769464
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A
Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive Prediction of IDH1 Mutation and ATRX Expression Loss in Low-Grade Gliomas Using Multiparametric MR Radiomic Features.
Ren Y; Zhang X; Rui W; Pang H; Qiu T; Wang J; Xie Q; Jin T; Zhang H; Chen H; Zhang Y; Lu H; Yao Z; Zhang J; Feng X
J Magn Reson Imaging; 2019 Mar; 49(3):808-817. PubMed ID: 30194745
[TBL] [Abstract][Full Text] [Related]
13. ATRX-dependent SVCT2 mediates macrophage infiltration in the glioblastoma xenograft model.
Shang J; Wang Y; Li Z; Jiang L; Bai Q; Zhang X; Xiao G; Zhang J
J Neurophysiol; 2022 May; 127(5):1309-1316. PubMed ID: 35417255
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of ATRX in gliomas.
Jalal JA; Rowandizy AIS; Ismael AT
Cell Mol Biol (Noisy-le-grand); 2020 Aug; 66(7):131-135. PubMed ID: 33287933
[TBL] [Abstract][Full Text] [Related]
15. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
16. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
17. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
19. ATRX loss in glioma results in dysregulation of cell-cycle phase transition and ATM inhibitor radio-sensitization.
Qin T; Mullan B; Ravindran R; Messinger D; Siada R; Cummings JR; Harris M; Muruganand A; Pyaram K; Miklja Z; Reiber M; Garcia T; Tran D; Danussi C; Brosnan-Cashman J; Pratt D; Zhao X; Rehemtulla A; Sartor MA; Venneti S; Meeker AK; Huse JT; Morgan MA; Lowenstein PR; Castro MG; Yadav VN; Koschmann C
Cell Rep; 2022 Jan; 38(2):110216. PubMed ID: 35021084
[TBL] [Abstract][Full Text] [Related]
20. Multicenter clinical radiomics-integrated model based on [
Zhang L; Pan H; Liu Z; Gao J; Xu X; Wang L; Wang J; Tang Y; Cao X; Kan Y; Wen Z; Chen J; Huang D; Chen S; Li Y
Eur Radiol; 2023 Feb; 33(2):872-883. PubMed ID: 35984514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
